The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has approved the use of Onswik, whose active ingredient is insulin efsitoalfα, for treating adult patients with type 2 diabetes mellitus. The key feature of the new drug is its dosing regimen — one injection per week instead of daily injections required with traditional insulin formulations. It is estimated that this could reduce the number of necessary injections from 365 to 52 per year for some patients, which could significantly simplify treatment and improve therapy adherence. Type 2 diabetes is a chronic disease in which the body loses the ability to effectively use insulin to regulate blood sugar levels. Many patients eventually require insulin therapy in addition to other treatment methods; however, the need for daily injections often becomes a barrier to treatment compliance. The development of medications with less frequent dosing intervals is considered by specialists an important step in improving the quality of life for people with diabetes. MHRA approval paves the way for Onswik to be used in clinical practice in the United Kingdom after undergoing the necessary procedures for assessing the drug's efficacy and safety.